Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Immunosuppressants Stories

2013-06-11 12:28:17

- Trial to Study the Innovative "Dissolving" Heart Device Compared to Abbott's Market-Leading Drug Eluting Stents in Patients with Coronary Artery Disease in Japan ABBOTT PARK, Ill., June 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb(TM) Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease.(1) The...

2013-06-07 23:16:34

Neurological Wellness Center physicians report the alleviation of depression is a predictable outcome of perispinal Enbrel treatment for traumatic brain injury. There is now substantial and accumulating basic science and clinical evidence linking neuro-inflammation with severe depression. (PRWEB) June 07, 2013 In a landmark study published in the Journal Neuropsychopharmacology, Susana G. Torres-Platas analyzed the brains of suicide victims and concludes: "The presence of hypertrophic...

2013-06-05 16:24:36

WHITE PLAINS, N.Y., June 5, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of lenalidomide (Revlimid®) to treat patients with mantle cell lymphoma (MCL) is encouraging news for these patients. "Despite advances in treatment, most mantle cell lymphoma patients relapse over time. So, lenalidomide is a welcome effective treatment option for these patients," said Clare Karten, senior director of mission education for The Leukemia & Lymphoma Society (LLS)....

2013-06-04 04:20:59

Fostamatinib at 100mg BID Significantly Improves Rheumatoid Arthritis in Both OSKIRA-2 & OSKIRA-3 SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). In the OSKIRA-2...

2013-06-03 08:25:49

Efficacy Advantages of TNF-Alpha Inhibitors Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., June 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai's Humira has the strongest clinical profile among key marketed products that...

2013-06-02 08:20:17

-- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1) EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor(®) (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior...

2013-05-30 12:27:17

However, Aubagio's Prescriber Base Continues to Lag Behind That of Novartis's Gilenya at Same Stage of Product Launch, According to a New Report from BioTrends Research Group EXTON, Pa., May 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of surveyed neurologists have prescribed Aubagio, the second oral disease-modifying agent (DMA) marketed for multiple sclerosis...

2013-05-29 23:25:36

Breakthrough Treatment Offers New Hope for the Brain Injured. (PRWEB) May 29, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from traumatic brain injury (TBI) since 2010. U.S. service persons, their spouses or caregivers will be greeted at the airport, chauffeured in our limousine to our Neurological Wellness Center for evaluation, treatment and caregiver training. Service persons who are unable to travel to our Neurological Wellness Center...

2013-05-30 00:20:34

-- At six months, adjusted mean treatment satisfaction scores increased by a statistically significant 20.4 with Gilenya vs. 2.9 with injectable disease modifying therapies1 EAST HANOVER, N.J., May 30, 2013 /PRNewswire/ -- People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya(®) (fingolimod) vs. switching to, or staying on, injectable interferon beta or glatiramer acetate, according to new study data...

2013-05-27 04:20:27

Company Receives CE Mark for COMBO Dual Therapy Stent(TM); Introduces Product in Europe and Markets in Asia Pacific and Middle East Regions HONG KONG, May 27, 2013 /PRNewswire/ -- OrbusNeich today launched the world's first dual therapy stent - the COMBO Dual Therapy Stent - to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease (CAD). The...